The new functionality identifies and flags patients whose symptoms and health history indicate possible COVID-19 infection
MARLBOROUGH, Mass. – March 17, 2020 – Persivia, a provider of real-time bundled payment, value-based care, population health, and quality management solutions, today announced the launch of a new COVID-19 surveillance module within its Soliton™ AI engine. Delivered as part of its CareSpace™ platform, this module uses data from multiple sources to identify patients who may have a COVID-19 novel coronavirus infection. With a shortage of tests for COVID-19, the ruleset will help healthcare professionals more effectively target patients who need to be tested. The new functionality rolls out this week and will be available to Persivia’s install base of 20 million covered lives across the country. The ruleset is being offered at no cost to public health departments across the country to help them manage the ongoing public health crisis.
The new Soliton™ module targets suspected COVID-19 cases by processing structured and unstructured data that Persivia acquires and normalizes from disparate sources, including real-time EHR data. The Soliton™ AI engine uses evidence-based algorithms to identify specific concepts and keywords in structured and unstructured data to identify potential cases of interest. Patients who are identified as having three or more relevant symptoms, as identified by CDC guidelines, such as fever, shortness of breath, and cough, are flagged with a level one alert. At this lowest level, the patient’s physician is prompted to educate the patient about COVID-19 and monitor their status. If Persivia also identifies a travel or exposure history the alert gets raised to a level two, where a CDC test is recommended.
Patients receive a level three alert when they are presumed positive for COVID-19 and level four when they are confirmed with symptoms. Medical professionals are also able to search for all patients flagged as possibly having COVID-19, and can filter them by alert level and symptoms.
It took less than 10 days for Persivia to bring this ruleset to production on its flexible, modular AI system. This speed-to-market will be critical in the coming weeks and months; Persivia will be able to adapt and add to the ruleset as we find out more about the disease, its symptoms, and progression. Similar rulesets can be developed for any health state, from other infectious diseases, to behavioral health and heart failure.
“In 2014, the medical world received a rude awakening about the fallibility of our fragmented healthcare system when a man with Ebola symptoms was erroneously discharged from the hospital,” said Fauzia Khan, MD, Persivia’s Chief Medical Officer. “The inability to match the documentation of travel history in the intake nurse’s notes with the symptoms coded by the physician was a flaw – one we have bridged with our ability to create evidence-based rulesets within CareSpaceTM. CareSpaceTM is built to acquire, aggregate, and normalize data from multiple sources which ensures it doesn’t miss any piece of recorded information about a patient from anywhere along the care continuum. This is critical when it comes to public health threats. We hope our ruleset will help healthcare organizations across the country identify the novel coronavirus in patients more quickly and effectively, leading to more appropriate testing, timely care, and better health outcomes.”